Navigation Links
kinetics in Medical Technology

Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

... postprandial times, combination with rHuPH20 yielded a profile of insulin kinetics and activity more like that of natural, endogenous prandial insulin ... mimic normal physiologic mealtime insulin release. "If these insulin kinetics can be replicated in studies with diabetic patients, the co-formulation of ...

New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder

... collaborated with Daiichi Sankyo and leveraged its insights into pathway kinetics to identify this new inflection point for the treatment of type 2 ... are the basis for particular diseases. KineMed's technology measures the kinetics of these pathways using a stable isotope labeling technique and mass ...

BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients

... Liver (EASL). The E.A.R.L.Y. study is an open-label, randomized, viral kinetics study of 69 antiviral-naive chronic hepatitis B e-antigen (HBeAg) ... E.A.R.L.Y. study (ETV-079) is a randomized, open-label, comparative viral kinetics study of antiviral-naive chronic HBeAg-positive patients evaluating ...

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

... "Our recent preclinical studies suggest that CTS-1027 treatment has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by uninfected liver cells. Interestingly, ...

AACR Data Highlights InNexus Preclinical Antibody Candidate

... Dose 100-Fold Above The Anticipated Therapeutic Dose ", (AACR# 1231) and " Oxidative Modification Of An Anti-CD20 Antibody Imparts Autophilic Binding kinetics ", (AACR# 1230). Posters and company representatives will also be available within the AACR Antibody and Antibody Targets Session from 1:00-5:00 PM ...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

... Scientific's first-generation TAXUS Express Stent. While the second-generation TAXUS Liberte Stent uses identical drug dose, polymer and release kinetics as the TAXUS Express Stent, it features thinner struts and a uniform architecture specifically designed for drug delivery. One-year results from ...

Breast MRI Scan Could Determine Need for Radiation Therapy

... dye used routinely in MRI scans not only highlights the size and location of the tumor but also details the blood vessels feeding the tumor. The kinetics or activity of the contrast dye in the tumor provided some key parameters for comparing MRI to traditional surgical tumor staging, he said. "MRI is ...

InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C

... of ITMN-191 given in combination with pegylated interferon alpha-2a (Pegasys(R)) and ribavirin on safety, efficacy, pharmacokinetics and viral kinetics compared to the effects in patients treated only with pegylated interferon alpha-2a and ribavirin. All patients will receive standard treatment ...

Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market

... was Neukine cleared from the patients' blood plasma just as quickly as the reference, but the number of neutrophils also increased with identical kinetics after treatment. We are very pleased with these results." The study was a single-dose, randomised, double-blind, two-way crossover trial and used ...

FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008

... show that ARI-2243 has an extremely high affinity (Ki of 27 picomolar) for the DPP-4 enzyme and drug dissociation from the enzyme is very slow. Such kinetics confer potency and long activity. During OGTT in normal mice, ARI- 2243 was 250 times more potent than sitagliptin and maximally lowered blood ...

Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting

... C Treated with Peginterferon Alfa-2b Plus Ribavirin; M. Martinot-Peignoux et al., Abstract 304, Saturday, Nov. 3, 2:00 pm, Exhibit Hall C Viral kinetics Can Quickly Predict Sustained Virological Response in HCV Patients with Normal ALT Treated with Pegylated Interferon Alfa-2b and Ribavirin: A ...

Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting

... failed to overcome. Preclinical studies demonstrate that trodusquemine is a potent, highly selective and reversible inhibitor of PTP- 1B. In vitro kinetics demonstrate that trodusquemine is a reversible, allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site ...

Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

... failed to overcome. Preclinical studies demonstrate that trodusquemine is a potent, highly selective and reversible inhibitor of PTP- 1B. In vitro kinetics demonstrate that trodusquemine is a reversible, allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site ...

Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting

... failed to overcome. Preclinical studies demonstrate that trodusquemine is a potent, highly selective and reversible inhibitor of PTP-1B. In vitro kinetics demonstrate that trodusquemine is a reversible, allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site ...

Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C

... Berrey, Pharmasset's Vice President, Clinical Development & Chief Medical Officer. "The 28-day endpoint will provide meaningful data on early viral kinetics and the proportion of patients who have undetectable HCV RNA by the end of this treatment period. We look forward to sharing the preliminary results ...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

... peptide vaccine. The primary endpoint of this analysis was to examine the kinetics of response to ipilimumab in 356 patients with stage III or stage IV ... as complete or partial response) and stable disease. Analysis of the kinetics of response data demonstrated: - Complete or partial response ...

Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV

... A Unique Viral kinetics Profile LAUSANNE, Switzerland, April 19, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development ...

Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation

... non-irradiated endothelial cells cultured with AEOL 10113 at 10ug (P less than 0.05). Laser scanning cytometry showed AEOL 10113 altered cell cycle kinetics and led to significantly (p less than 0.05) increased G1 population 48 hours following irradiation. The Potential for Metalloporphyrin ...

InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting

... Disease Week (DDW) meeting being held May 19-24 in Washington, D.C. The reported study (DDW abstract #M1816) examined ITMN-191 potency and binding kinetics in biochemical assays. The new InterMune study represents an in-depth characterization of the mechanism of inhibition of the HCV NS3/4A serine ...

Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients

... than adefovir at 48 weeks -- a result that was also seen at weeks 12 (primary endpoint) and 24. These data from an open-label, randomized viral kinetics study of 69 antiviral-naive chronic hepatitis B e-antigen (HBeAg) positive patients were presented at the annual Digestive Disease Week(R) meeting. ...

Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine

... pain in supervised healthcare settings. It employs the patented and proprietary, Chysis(R) drug-delivery platform to adhere and regularize the kinetics of morphine to and across the nasal mucosa. Each nostril can hold only 150-200 ul of administered drug candidate and requires approximately 15 ...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

... said Douglas Mayers, M.D., executive vice president and chief medical officer of Idenix Pharmaceuticals. "We are very pleased with the viral kinetics and HCV RNA clearance rates observed in patients treated with triple combination therapy in this study and look forward to further development of ...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

... studies show that ARI-2243 has an affinity (Ki) of 27 picomolar, binding tightly to DPP-4 and dissociating very slowly from the enzyme. Such binding kinetics confer potency and long activity. Specifically, during OGTT in normal mice, ARI-2243 produced far greater lowering of plasma glucose compared ...

Prothrombin Time Comes in Small (CLIA-Waived) Packages

... analysis of coagulation levels during mobile emergency treatment, in hospital and in general practice. The device employs electromagnetic field kinetics to determine PT. A single drop (10 l) of capillary or venous whole blood is applied to a test strip containing thromboplastin, initiating the ...
Other Contents
(Date:7/29/2014)... The University of Maryland Schools of Dentistry (UM ... that they have received a five-year $10.7 million ... and Infectious Diseases (NIAID) of the National Institutes ... treatment of sexually-transmitted diseases (STDs). The grant, which ... program, represents a new direction for the research ...
(Date:7/29/2014)... thirty days to go and almost 2500 registered participants, ... well underway. The event, a joint venture between the ... French Society for Biochemistry and Molecular Biology (SFBBM), will ... September at the Palais des Congrs in Paris, France. ... for the life sciences in Europe this year. It ...
(Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2
(Date:7/29/2014)... 29, 2014 As the Ebola outbreak in ... partners to both purchase critical emergency supplies locally, as well ... Liberia. These supplies will contain materials used to control the ... populated areas of the country. , With a large ... response to the Ebola outbreak in the region. The current ...
(Date:7/29/2014)... July 29, 2014 The Board of Governors ... & Hart LLP ’s Connie Akridge to serve ... serves as President of the Foundation. Akridge served as President ... is a partner at Holland & Hart in Las Vegas, ... regulatory/administrative matters to insurance and healthcare clients for more than ...
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... leading pediatricians have joined our network, CarePoint Health ... and Dr. Sushma Kaki. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Historically, Memorial ... the United States usually celebrated throughout that time by ... those summer days now mark the start of a ... involving teen drivers. In 2012 nearly 1.000 people ... period from Memorial Day to Labor Day. , The ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2
Other TagsOther Tags